Current treatment paradigms for locally advanced non-small cell lung cancer

James R. Rigas, Karen Kelly

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Locally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challenging to manage. The majority of patients can be appropriately treated with a combination of chemotherapy and radiation therapy; however, a subset of stage III patients who are considered surgical candidates may require a modification of this plan. For example, a trimodal approach using chemoradiation followed by surgery may be beneficial for fit patients with bulky mediastinal disease who are candidates for lobectomy, whereas patients with minimal mediastinal nodal involvement may receive only chemotherapy before surgical resection. No standard chemotherapy exists for this group of stage IIIA resectable patients. Phase II data from studies employing neoadjuvant cisplatin combinations suggest that these regimens are active and well tolerated. For patients with unresectable stage III NSCLC, concurrent chemoradiation is the standard of care at the present time for patients with good performance status, good pulmonary function tests, and an acceptable volume of normal lung receiving 20 Gy (V20). To manage distant micrometastasis further, induction and consolidation regimens are under investigation during which full-dose chemotherapy is administered either before (as induction) or after (as consolidation) concurrent chemoradiotherapy. To date, consolidation docetaxel after concurrent etoposide, cisplatin and thoracic radiation has shown encouraging survival results in a large Southwest Oncology Group phase II trial. This article will review the current treatment strategies for stage III NSCLC.

Original languageEnglish (US)
JournalJournal of Thoracic Oncology
Volume2
Issue numberSUPPL. 2
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
docetaxel
Drug Therapy
Cisplatin
Therapeutics
Mediastinal Diseases
Neoplasm Micrometastasis
Respiratory Function Tests
Chemoradiotherapy
Etoposide
Standard of Care
Combination Drug Therapy
Radiotherapy
Thorax
Radiation
Lung
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Consolidation
  • Docetaxel
  • Etoposide
  • Non-small cell lung cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Current treatment paradigms for locally advanced non-small cell lung cancer. / Rigas, James R.; Kelly, Karen.

In: Journal of Thoracic Oncology, Vol. 2, No. SUPPL. 2, 2007.

Research output: Contribution to journalArticle

@article{f57f0eacf2f54e31937ac1b402dc34f6,
title = "Current treatment paradigms for locally advanced non-small cell lung cancer",
abstract = "Locally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challenging to manage. The majority of patients can be appropriately treated with a combination of chemotherapy and radiation therapy; however, a subset of stage III patients who are considered surgical candidates may require a modification of this plan. For example, a trimodal approach using chemoradiation followed by surgery may be beneficial for fit patients with bulky mediastinal disease who are candidates for lobectomy, whereas patients with minimal mediastinal nodal involvement may receive only chemotherapy before surgical resection. No standard chemotherapy exists for this group of stage IIIA resectable patients. Phase II data from studies employing neoadjuvant cisplatin combinations suggest that these regimens are active and well tolerated. For patients with unresectable stage III NSCLC, concurrent chemoradiation is the standard of care at the present time for patients with good performance status, good pulmonary function tests, and an acceptable volume of normal lung receiving 20 Gy (V20). To manage distant micrometastasis further, induction and consolidation regimens are under investigation during which full-dose chemotherapy is administered either before (as induction) or after (as consolidation) concurrent chemoradiotherapy. To date, consolidation docetaxel after concurrent etoposide, cisplatin and thoracic radiation has shown encouraging survival results in a large Southwest Oncology Group phase II trial. This article will review the current treatment strategies for stage III NSCLC.",
keywords = "Chemotherapy, Cisplatin, Consolidation, Docetaxel, Etoposide, Non-small cell lung cancer, Radiotherapy",
author = "Rigas, {James R.} and Karen Kelly",
year = "2007",
doi = "10.1097/01.JTO.0000269735.21209.bc",
language = "English (US)",
volume = "2",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Current treatment paradigms for locally advanced non-small cell lung cancer

AU - Rigas, James R.

AU - Kelly, Karen

PY - 2007

Y1 - 2007

N2 - Locally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challenging to manage. The majority of patients can be appropriately treated with a combination of chemotherapy and radiation therapy; however, a subset of stage III patients who are considered surgical candidates may require a modification of this plan. For example, a trimodal approach using chemoradiation followed by surgery may be beneficial for fit patients with bulky mediastinal disease who are candidates for lobectomy, whereas patients with minimal mediastinal nodal involvement may receive only chemotherapy before surgical resection. No standard chemotherapy exists for this group of stage IIIA resectable patients. Phase II data from studies employing neoadjuvant cisplatin combinations suggest that these regimens are active and well tolerated. For patients with unresectable stage III NSCLC, concurrent chemoradiation is the standard of care at the present time for patients with good performance status, good pulmonary function tests, and an acceptable volume of normal lung receiving 20 Gy (V20). To manage distant micrometastasis further, induction and consolidation regimens are under investigation during which full-dose chemotherapy is administered either before (as induction) or after (as consolidation) concurrent chemoradiotherapy. To date, consolidation docetaxel after concurrent etoposide, cisplatin and thoracic radiation has shown encouraging survival results in a large Southwest Oncology Group phase II trial. This article will review the current treatment strategies for stage III NSCLC.

AB - Locally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challenging to manage. The majority of patients can be appropriately treated with a combination of chemotherapy and radiation therapy; however, a subset of stage III patients who are considered surgical candidates may require a modification of this plan. For example, a trimodal approach using chemoradiation followed by surgery may be beneficial for fit patients with bulky mediastinal disease who are candidates for lobectomy, whereas patients with minimal mediastinal nodal involvement may receive only chemotherapy before surgical resection. No standard chemotherapy exists for this group of stage IIIA resectable patients. Phase II data from studies employing neoadjuvant cisplatin combinations suggest that these regimens are active and well tolerated. For patients with unresectable stage III NSCLC, concurrent chemoradiation is the standard of care at the present time for patients with good performance status, good pulmonary function tests, and an acceptable volume of normal lung receiving 20 Gy (V20). To manage distant micrometastasis further, induction and consolidation regimens are under investigation during which full-dose chemotherapy is administered either before (as induction) or after (as consolidation) concurrent chemoradiotherapy. To date, consolidation docetaxel after concurrent etoposide, cisplatin and thoracic radiation has shown encouraging survival results in a large Southwest Oncology Group phase II trial. This article will review the current treatment strategies for stage III NSCLC.

KW - Chemotherapy

KW - Cisplatin

KW - Consolidation

KW - Docetaxel

KW - Etoposide

KW - Non-small cell lung cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=34250855750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250855750&partnerID=8YFLogxK

U2 - 10.1097/01.JTO.0000269735.21209.bc

DO - 10.1097/01.JTO.0000269735.21209.bc

M3 - Article

C2 - 17589303

AN - SCOPUS:34250855750

VL - 2

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - SUPPL. 2

ER -